FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:965-967 March 2, 2006 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Polman, C. H. Related Article by Rudick, R. A. Related Article by Yousry, T. A. PubMed Citation

Natalizumab, a recombinant monoclonal antibody against ₄ integrins, is the first selective immunomodulating drug for the treatment of multiple sclerosis and, by several criteria, is an advance over current therapies. The antibody was developed to block the adhesion of activated T cells to endothelial cells and thereby reduce the inflammatory feature of the multiple sclerosis plaque. Parenthetically, this advance attests to the value of translational research in a disease for which there is only partial knowledge of the mechanism. Natalizumab has also evinced interest for the treatment of Crohn's disease and rheumatoid arthritis but with less certain results in limited trials. . . . [Full Text of this Article]

Source Information

From the Department of Neurology, Caritas St. Elizabeth's Medical Center, Boston.

Related Letters:

Natalizumab for Relapsing Multiple Sclerosis
Tenser R. B., Jeffery D. R., Meyer M. A., Polman C. H., Rudick R. A., Major E. O., Yousry T. A., Clifford D. B., Ropper A. H.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:2387-2389, Jun 1, 2006. Correspondence

This article has been cited by other articles:

• Steiner, I., Holloway, R.G., Thompson, J.P., Noyes, K., Dorsey, E.R., Schwid, S.R. (2009). QUANTITATIVE RISK-BENEFIT ANALYSIS OF NATALIZUMAB. Neurology 72: 1791-1792 [Full Text]  
• Ransohoff, R. M. (2007). Natalizumab for Multiple Sclerosis. NEJM 356: 2622-2629 [Full Text]  
• Tenser, R. B., Jeffery, D. R., Meyer, M. A., Polman, C. H., Rudick, R. A., Major, E. O., Yousry, T. A., Clifford, D. B., Ropper, A. H. (2006). Natalizumab for relapsing multiple sclerosis.. NEJM 354: 2387-2389 [Full Text]  
• (2006). Risk for PML with Natalizumab. JWatch Infect. Diseases 2006: 5-5 [Full Text]